
2Firsts, reporting from Shenzhen - On the evening of March 17, Smoore International Holdings Limited (referred to as "Smoore", stock code: 6969) released its 2024 earnings report.
According to the financial report, Smoore reported a total revenue of 11.799 billion yuan (about $1.63 billion) in 2024, marking a 5.3% increase from the previous year. However, net profit fell by about 20% to around 1.3 billion yuan (around $180 million).

Revenue from Smoore’s self-owned brand business reached 2.475 billion yuan (around $340 million), accounting for 21% of total revenue, up 34% year-on-year.
Revenue from corporate client oriented business totaled 9.324 billion yuan (about $1.29 billion), making up 79% of total revenue, down 0.3% from the previous year.
Speifically, Smoore's revenue from Europe and other markets rose 8.7% year-on-year to 5.512 billion yuan (around $760 million), making up 46.7% of total revenue. U.S. revenue climbed 15.5% to 1.399 billion yuan (about $190 million), accounting for 11.9%.
Mainland of China revenue increased 12.9% to 1.011 billion yuan (around $140 million), representing 8.6% of the total. Revenue from Hong Kong, China, however, fell 3.7% to 3.876 billion yuan (around $540 million), contributing 32.8% to overall revenue.
In addition, Smoore's research and development expenses rose 6% year-on-year to 1.57 billion yuan (about $220 million) in 2024, accounting for 13.3% of total revenue. The increase was mainly driven by investment in medical atomization and heated tobacco (heat-not-burn) products.
The management expressed confidence in the company's long-term growth and stated that they will continue to focus on the core technology of atomization, expanding their business in areas such as electronic atomization, HNB (heat-not-burn) products, special purpose atomization products, inhalation therapy, and beauty atomization.
The company plans to further optimize collaboration models by 2025, offering more customized services to meet rapidly changing market demands.
2Firsts will provide an analysis of Smoore International's 2024 annual report. Stay tuned.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com